Reminer of where this is going: "October 18, 2004 Peregrine Pharmaceuticals Announces Successful Completion of its Antibody Humanization Project with AERES Biomedical TUSTIN, Calif., October 18 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced today that AERES Biomedical Ltd. (London, UK) had successfully completed the humanization of its 3G4 antibody that recognizes the phospholipid, phosphatidylserine. The 3G4 antibody is part of Peregrine's Anti-Phospholipid Therapy(APT) platform technology. Human or humanized monoclonal antibodies are ideal components of drugs that may be administered multiple times to individual patients because they are expected to not be recognized as foreign by the patient's immune system. "The humanized version of the 3G4 antibody is an important addition to Peregrine's VTA and APT platform technologies," said Steve King, Peregrine's president and chief executive officer. "We will begin preparing the humanized 3G4 antibody for cGMP manufacturing and evaluate the antibody for the treatment of cancer and viral diseases. The humanized antibody will also be evaluated as a carrier for therapeutic agents for vascular targeting applications."
Dr. Tarran Jones, chief executive officer of AERES, said, "We are delighted to have been able to provide Peregrine with a humanized version of its 3G4 antibody. The project was completed on schedule and the resulting antibody retained all desired binding characteristics. This collaborative project marks the 25th monoclonal antibody that we have successfully humanized using our proprietary humanization technology."
